Peptides for Joint Pain: BPC-157, TB-500, Lorecivivint, Pentosan and Collagen Peptides, Evidence Tiered

Which joint pain peptides have human evidence?

Legal status first: none of these is an approved treatment for joint pain. Lorecivivint is waiting on an FDA decision. BPC-157 and TB-500 are unapproved. On July 23, 2026, an FDA advisory panel voted 8 to 6 in their favor, against FDA staff. The panel's reason was that a pharmacy beats the gray market, not that they work, and the vote is not binding (see the FDA status tracker). Collagen peptides are food supplements. Pentosan polysulfate shots are still being tested. Below, each is sorted by what has been done in people, with hyaluronic acid shots as the yardstick.

One thing to know before you read a table like this. A proper study in a few hundred people costs millions. That money almost always comes from whoever will own the drug at the end. Nobody can own some of these. They are a natural piece of a body protein, or a recipe published decades ago, or something already sold cheap. So nobody pays for the study, and the research stops at animals. For those, a missing study tells you how drug research gets paid for. It tells you nothing about whether the stuff works. That cuts both ways, just as hard. With no study, something that does nothing and something that causes a rare harm both look like something with no reported problems. No evidence here really means no evidence, in both directions. It is not a quiet thumbs up.

How do hyaluronic acid injections compare?

Joint-lubricant shots are the widely used joint treatment that peptide ads quietly compete with. This review is a lesson in how small studies, where everyone knows who got what, puff up an effect. The five unpublished studies it tracked down showed no effect at all (PubMed 22868835). Many studies in people, very little effect.

Is lorecivivint going to be approved for knee osteoarthritis?

Lorecivivint (SM04690) is not a peptide. It is a small-molecule drug that tunes a growth signal called Wnt. In the big studies it was given as a single 0.07 mg knee shot. OA-10 put 498 patients with moderate knee arthritis (grade 2 to 3 on X-ray) on the drug or a dummy shot. It 'failed to meet the primary endpoint' on pain at week 12. A look back afterwards found a hint of benefit in the milder grade 2 group (Clinical and Experimental Rheumatology, OA-10). OA-11 followed 513 patients for 56 weeks. Pain at week 12 fell 2.24 points on lorecivivint and 2.49 on the dummy shot. Neither group lost much joint space over 52 weeks, so the cartilage measure couldn't tell them apart either (PubMed 39808286). Big studies in people, no win on symptoms.

The request rests instead on OA-07, a two-year big study. Patients given a shot once a year 'maintained and ultimately improved their medial JSW', meaning the space inside the joint where cartilage sits. Patients on the dummy shot who switched to the drug also gained joint space (Biosplice press release, January 6, 2026). If the FDA accepts a cartilage measure without a win on pain, lorecivivint would be the first drug that changes the course of arthritis. That is a big 'if'. And here is the point for peptide comparisons: it has run the studies the peptides have not, and it still may not clear the bar.

Do collagen peptides help joint pain?

Collagen peptides are the odd one out here. They are digested into small peptides and protein building blocks, they are sold as food, and they have more studies in people than anything injected apart from lorecivivint. In the 2008 Penn State study, 147 college athletes with joint pain from activity, and no joint disease, took 10 g of collagen or a dummy drink every day for 24 weeks. Among the 97 with full data, pain when walking, standing, resting, carrying and lifting improved more on collagen, by roughly half a point on 10-point scales (Current Medical Research and Opinion, 2008). The 2017 study gave 139 active adults with knee pain during activity 5 g of collagen peptides or a dummy drink for 12 weeks. Pain during activity fell 19.5 mm on collagen and 13.9 mm on the dummy (Applied Physiology, Nutrition, and Metabolism, 2017). Proper studies in people, small effect.

For arthritis, as opposed to sports knee pain, the data are thinner. A 30-person study at one clinic, in people with mild knee arthritis, used a special MRI to measure cartilage over 24 weeks. Scores rose in two spots in the knee on collagen and fell on the dummy drink, but symptoms were no different (Osteoarthritis and Cartilage, 2011). A scan change without a symptom change in 30 people is a reason for a bigger study, not a conclusion.

Where does pentosan polysulfate stand?

Pentosan polysulfate is a partly lab-made sugar chain, not a peptide. In the 2005 study, morning stiffness was shorter and pain at rest was lower at several points (Current Therapeutic Research, 2005). That was a small, proper study in people. The 2026 study gave 61 people shots under the skin twice a week, once a week or a dummy shot for 39 days. The ARGS drop was the one marker that clearly changed (Arthritis Research and Therapy, 2026). The big study, PARA_OA_012, gives 2 mg/kg under the skin twice a week for six weeks at 65 sites. Its main measure is average daily pain at day 112 (Paradigm big-study sign-up report).

What about TB-500 and thymosin beta-4?

People often say this pair has 'animal data only', and that is wrong both ways. There is real data in people on thymosin beta-4, and it is not small. A company called RegeneRx ran three dry eye studies of thymosin beta-4 eye drops (RGN-259) against dummy drops: ARISE-1 (317 people), ARISE-2 (601) and ARISE-3 (700). ARISE-3 missed both of its main goals. Damage on the eye surface changed by minus 0.41 on the drug and minus 0.46 on the dummy drop. Eye discomfort changed by minus 0.4 in both groups (ClinicalTrials.gov results, NCT03937882). In a 72-patient study of pressure sores, where the main goal was safety, 8 of 54 on thymosin beta-4 (across three doses) healed by day 84, against 3 of 18 on a dummy treatment (NCT00382174).

Two smaller studies looked good. In a big-stage study of a rare eye-surface disease (neurotrophic keratopathy), 6 of 10 treated eyes healed completely by day 29, against 1 of 8 on dummy drops. That fell just short of a clear result on the main test (International Journal of Molecular Sciences, 2022). In a 9-patient study of severe dry eye, eye discomfort dropped 35.1 percent and eye surface damage 59.1 percent at day 56 (Cornea, 2015). Beyond the eye, there are mid-sized studies in leg ulcers and a stopped study in a rare skin-blistering disease (epidermolysis bullosa). There is also an early drip-into-the-vein study in 30 healthy volunteers, at 0.5 to 5.0 micrograms per kilogram for ten days, with no results posted (NCT04555850). And two finished Chinese studies in heart attack have not posted results either.

So the honest summary of the full protein is not that it is untested. It has been tested again and again, mostly in the eye, and the biggest, best-run study did not beat the dummy drop. That is a stronger and more useful thing to say than 'no human evidence', and it points the opposite way from the ads.

TB-500 is not that protein. It is a lab-made piece seven building blocks long (building blocks 17 to 23 of thymosin beta-4), and it has never been studied in people. One ClinicalTrials.gov record carries its name, NCT07487363, and nobody should cite it. The record's own summary opens by saying it is a made-up example of a registry entry, not a real study. If you see TB-500 described as being in an early heart study, that record is where the claim comes from. TB-500 has animal studies only, and no data from people of any kind.

Does BPC-157 work for joint pain in humans?

The HSS Journal review searched 1993 to June 2024. It found no safety data from people at all, and only the one knee report (PubMed 40756949). It says BPC-157 lasts under 30 minutes in the body. That leaves open how something cleared so fast could have lasting effects on a joint. Nobody has measured it in people. BPC-157's reputation for muscles and joints comes from rat work by the Zagreb group. It also comes from a study of rat Achilles tendon cells in a dish, where the cells grew out faster, survived damage better and moved more at higher doses (Journal of Applied Physiology, 2011).

Pentadeca arginate, sold as a legal stand-in for BPC-157, is the same sequence with a different salt, and it has no studies of its own. GHK-Cu shows up in 'joint stacks' like the KLOW and Wolverine blends. Its evidence is for skin, from creams, and we found no joint study in any species.

What the animal study on joints showed

The only joint-related evidence for thymosin beta-4 is a rat study. 1 microgram of thymosin beta-4 in a surgical glue made a healing knee ligament stronger at four weeks, with neater, thicker collagen fibers (Regulatory Peptides, 2013). Note what it used: the full protein, placed right in the wound in glue. Vials sold as TB-500 hold a shorter piece that people inject somewhere else in the body. That gap between the study and the product runs through every compound at the bottom of this page.

The bottom line

The two peptides with the loudest joint-repair ads, BPC-157 and TB-500, have the least joint evidence in people on this page. That is narrower than 'no human evidence'. Thymosin beta-4 has been given to thousands of people, and BPC-157 to a handful. But those studies were in eyes, skin, hearts and one knee report looked at afterwards, not in proper joint studies. Lorecivivint ran the biggest studies, twice failed to beat a dummy shot on pain, and is asking the FDA to approve it on cartilage measures instead. Plain collagen peptides have the steadiest, if modest, results in people. And the common joint shot barely works when studies are done properly. People given a dummy joint shot often feel a lot better. That is why a 12-patient report on BPC-157 knee shots, with nobody to compare against, can't tell you anything. For safety, see peptide side effects by class.